• Reyes María Martín-Rojas, Gloria Pérez-Rus, Valeria Estefania Delgado-Pinos, Amalia Domingo-González, Isabel Regalado-Artamendi, Natalia Alba-Urdiales, Pablo Demelo-Rodríguez, Silvia Monsalvo, Gabriela Rodríguez-Macías, Monica Ballesteros, Santiago Osorio-Prendes, José Luis Díez-Martín, and Cristina Pascual Izquierdo.
• Department of Hematology, University General Hospital Gregorio Marañon, Madrid, Spain.
• Eur. J. Haematol. 2020 Dec 1; 105 (6): 741-750.

BackgroundAbnormal coagulation parameters have been reported in COVID-19-infected patients. Although the underlying mechanism of COVID-19 coagulopathy remains unknown, it has been suggested to be a form of disseminated intravascular coagulation (DIC).ObjectivesThe aim of our study was to analyze the coagulation parameters of patients with COVID-19, determine whether coagulation factors consumption occurs and identify potential prognostic biomarkers of the disease.Patients/MethodsBlood samples from hospitalized patients with COVID-19 pneumonia were collected. We performed basic coagulation tests and quantification of coagulation factors and physiological inhibitor proteins. Laboratory data were compared with clinical data and outcomes.ResultsThe study involved 206 patients (63.6% male). D-dimer was particularly elevated (median 450 ng/mL; IQR 222.5-957.3). Free protein S levels were below the normal range (median 56.6%; IQR: 43.6-68.9), and factor VIII showed an increasing trend (median 173.4%; IQR: 144.1-214.9). However, all coagulation factors were within normal limits. We found no correlation between abnormal coagulation parameters and thrombosis, except for higher D-dimer (HR 1.99; 95% CI 1.3-3.1; P = .002).ConclusionsCOVID-19 is associated with coagulopathy that correlates with poor prognosis. However, we did not demonstrate a consumption of coagulation factors, as seen in DIC.© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

62 keywords...

hide…